Category - Developments

IntelGenx (OTCQX:IGXT; TSX-V:IGX) strengthened its relationship with Chemo Group by signing a term sheet for co-development and commercialization of a generic tablet for the central nervous system (CNS) on a worldwide...

Oramed Pharmaceuticals (NASDAQ:ORMP) has successfully concluded a Phase 1b study of ORMD-0901, its oral GLP-1 analog, in Type 2 diabetes patients. The study showed ORMD-0901 to be safe and well tolerated, having no...

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant was named a gold award winner at the 13th annual Stevie Awards for Women in Business in the category of “Best New Product or Service of the Year.”...

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has signed a binding term sheet to license Eli Lilly’s tadalafil dosing patent. Any exclusivity associated with the tadalafil compound patent is not affected by the agreement...

Britain’s Computer Business Review has selected Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant as one of 10 future technologies that will change the world, along with autonomous vehicles, bionic exoskeletons...

Profound Medical (TSX-V:PRN) has completed a bought deal offering of 15.82 million common shares at a price of $1.10 each for gross proceeds of about $17.4-million. The offering was completed through a syndicate of...

Avivagen (TSX-V:VIV) has signed an agreement with Shaanxi Jintai Mining, a widely diversified Chinese company, to form a joint venture company to commercialize OxC-beta Livestock in China. The JV will initially target...

BioTuesdays’ Stephen Kilmer joins Titan management, directors and guests at the bell closing ceremony. Katherine Beebe, executive VP and chief development officer of Titan Pharmaceuticals (NASDAQ:TTNP)...

After an end-of-Phase 2 meeting with the FDA, Aurinia Pharmaceuticals (NASDAQ:AUPH) plans to begin a single Phase 3 clinical trial for voclosporin in the treatment of lupus nephritis (LN). Aurinia believes the Phase 3...

Closely-held Turnstone Biologics has completed a $41.4-million series B financing led by new investor, OrbiMed, with participation from another new investor, F-Prime Capital Partners, and existing investors, FACIT and...